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A stability-indicating reverse phase–high performance liquid chromatography (RP–HPLC) method was
developed and validated for the determination of atazanavir sulfate in tablet dosage forms using C18
column Phenomenix (250 mm4.6 mm, 5 μm) with a mobile phase consisting of 900 mL of HPLC grade
methanol and 100 mL of water of HPLC grade. The pH was adjusted to 3.55 with acetic acid. The mobile
phase was sonicated for 10 min and ﬁltered through a 0.45 μm membrane ﬁlter at a ﬂow rate of 0.5 mL/
min. The detection was carried out at 249 nm and retention time of atazanavir sulfate was found to be
8.323 min. Linearity was observed from 10 to 90 μg/mL (coefﬁcient of determination R2 was 0.999) with
equation, y¼23.427xþ37.732. Atazanavir sulfate was subjected to stress conditions including acidic,
alkaline, oxidation, photolysis and thermal degradation, and the results showed that it was more sen-
sitive towards acidic degradation. The method was validated as per ICH guidelines.
& 2015 Xi'an Jiaotong University. Production and hosting. Published by Elsevier B.V. All rights reserved.1. Introduction
Atazanavir sulfate, chemically known as 3,12-bis(1,1-dimethy-
lethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyr-
idinyl)phenyl)methyl)-, dimethyl ester, [1] (Fig. 1) is a white to pale
yellow powder, slightly soluble in water. It, in combination with
other antiretroviral agents, is used in the treatment of human
immunodeﬁciency virus (HIV-1) infection. Atazanavir formulated
as 1:1 sulfate salt is the most recently introduced azapeptide in-
hibitor of HIV-1 protease. The drug was approved by the United
States Food and Drug Administration (USFDA) in June 2003. An-
tiretroviral drugs are medications for the treatment of infection by
retroviruses, primarily HIV. When several such drugs, typically
three or four, are taken in combination, the approach is known as a
highly active antiretroviral therapy (HAART). The American Na-
tional Institutes of Health and other organizations recommend
offering antiretroviral treatment to all patients with AIDS [2].
Structure activity studies with a series of azadipeptides were de-
signed to mimic the transition state of the peptide-cleavage re-
action catalyzed by HIV-1 protease identiﬁed lead compounds that
have either potent antiviral activity against mutant HIV-1 strains
or good oral bioavailability [3]. Lead optimization using X-ray
structural data from an inhibitor–protease complex [4] led to theon and hosting. Published by Elsev
niversity.
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(2015), http://dx.doi.org/10discovery of atazanavir sulfate, which showed an excellent anti-
viral activity with high oral bioavailability and could be used in
combination with other antiretroviral agents [5]. Recently, a new
method has been developed for the estimation of in vitro dis-
solution assessment of atazanavir and ritonavir in combined tablet
dosage forms by the RP–HPLC method [6,7]. An literature survey
reveals that atazanavir is quantitatively assayed in biological ﬂuids
either individually [8] or in the presence of other retroviral drugs
using liquid chromatography [9,10]. The literature survey also in-
dicates that its pharmacokinetics studies in healthy volunteers
have been done [11]. However, some UV–vis spectrophotometric
methods were proposed for the estimation of atazanavir in bulk
and pharmaceutical dosage forms [12–14]. According to ICH
guidelines [15,16], our present work not only developed and va-
lidated a method, but also was a stability-indicating study. A de-
gradation product is an impurity resulting from a chemical change
in the drug substance brought during manufacture and/or storage
of the new drug product by factors such as light, temperature, pH,
water or by the reaction with an excipient and/or the immediate
container closure system.2. Materials and methods
2.1. Chemicals
The reagents used in this work were methanol (HPLC grade –
Lichrosolv), acetic acid, HCl (AR), NaOH (AR), and hydrogenier B.V. All rights reserved.
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Fig. 1. Chemical structure of atazanavir sulfate.
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Distilled water (HPLC grade) was obtained from Lichrosolv (Merck,
India). Atazanavir sulfate capsules were procured from Bristol
Mayer Squibb and the membrane ﬁlter was procured from Lily
Pour, India.
2.2. Equipment
The instruments used in the study were electronic balance
(Sigma 200), sonicator (PCi, 3.5 L), hot air oven (Universal Hot Air
Oven), and digita pH meter (Unilab). HPLC (Shimadzu, Kyoto, Ja-
pan) was monitored and integrated using empower software.
Additionally, syringe [Hamilton (Rheodyne-20 μL)] and syringe
ﬁlter [Himedia Syringe-driven ﬁlters (0.22 μm)] were used.
2.3. Chromatographic conditions
A number of HPLC systems were investigated to optimize the
separation of atazanavir sulfate. HPLC system was composed of an
LC-20AT Prominence solvent delivery module, a manual rheodyne
injector with a 20-μL ﬁxed loop and an SPD-20A Prominence UV–
visible detector. Separation was performed on a Phenomenex C18
column (250 mm4.6 mm i.d., 5 mm.; Phenomenex, Torrance,
USA) at ambient temperature. The data acquisition was made with
Spinchrom Chromatographic Station
s
CFR Version 2.4.0.195
(Spinchrom Pvt. Ltd., Chennai, India). The mobile phase consisted
of 900 mL of HPLC grade methanol and 100 mL of water of HPLC
grade, with the pH adjusted to 3.55 with acetic acid. The mobile
phase was sonicated for 10 min and ﬁltered through a 0.45 μm
membrane ﬁlter. The mobile phase ﬂow rate was maintained at
0.5 mL/min and eluents were monitored at 249 nm. The samples
were injected using a 20 μL ﬁxed loop. All determinations were
performed at ambient temperature for a run time of 10 min. The
optimized chromatographic conditions are shown in Table 1.
2.4. Method development
2.4.1. Selection and preparation of mobile phase
Various mobile phases containing methanol, water, acetonitrile,Table 1
Optimized chromatographic conditions of atazanavir sulfate.
Parameters Conditions
Stationary phase (column) C18 (250 mm4.6 mm, 5 μm)
Mobile phase Methanol: water (90:10, v/v),
pH adjusted to 3.55
Flow rate (mL/min) 0.5
Run time (min) 10
Column temperature Ambient temperature
Volume of injection loop (mL) 20
Detection wavelength (nm) 249
Retention time (min) 8.323
Please cite this article as: S. Dey, et al., Development and validati
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ﬂow rates. Good symmetrical peak was found with the mobile
phase comprising methanol and water in the ratio 90:10 (v/v) (pH
adjusted to 3.55 with glacial acetic acid).
Mobile phase was prepared by mixing 900 mL of HPLC grade
methanol with 100 mL of water of HPLC grade, and the pH was
adjusted to 3.55 with acetic acid. The mobile phase was sonicated
for 10 min and ﬁltered through the 0.45 μm membrane ﬁlter.
2.4.2. Preparation of standard stock solutions
The standard stock solutions of 100 μg/mL of the drug were
prepared by dissolving 50 mg of pure drug in the mobile phase in a
50 mL volumetric ﬂask and the volume was made up to the mark.
Resulting solutions were further diluted with mobile phase to
obtain a ﬁnal concentration of 100 μg/mL and stored under
refrigeration.
2.4.3. Preparation of calibration curve
Aliquots of standard stock solutions were put in a 10 mL vo-
lumetric ﬂask and diluted up to the mark with mobile phase. In
such a way, the ﬁnal concentrations of the drug were in the range
of 10–90 μg/mL. Triplicate injections of 20 μL were made and
analyzed by chromatograph under the conditions as described
above. Evaluation of the drug was performed and peak areas were
recorded. Calibration curves were constructed by plotting the peak
area on the y-axis against respective concentration of the drug on
the x-axis. The calibration curve was evaluated by its coefﬁcient of
determination (R2).
2.5. Method validation
The developed method was validated by evaluating linearity,
accuracy, precision, robustness, ruggedness, detection limit,
quantiﬁcation limit and stability. Coefﬁcients of variation and re-
lative errors of less than 2% were considered acceptable, except for
the quantiﬁcation limit, for which these values were established at
2%, as recommended in the literature [15].
2.5.1. Linearity
A stock solution of atazanavir sulfate of 1000 μg/mL was pre-
pared with mobile phase. From it, various working standard so-
lutions were prepared in the range of 10 to 120 μg/mL and injected
into HPLC. It was shown that the selected drug had linearity in the
range of 10–90 μg/mL. The calibration plot (peak area ratio of
atazanavir sulfate versus atazanavir sulfate concentration) was
generated by replicate analysis (n¼9) at all concentration levels
and the linear relationship was evaluated using the least square
method within Microsoft Excel
s
program.
2.5.2. Accuracy
The accuracy of the method was carried out using one set of
different standard addition methods at different concentration
levels, 80%, 100% and 120%, and then comparing the difference
between the spiked value (theoretical value) and actual found
value.
2.5.3. Precision
The precision of the method was ascertained from the peak
area obtained by actual determination of six replicates of a ﬁxed
amount of the drug (50 μg/mL). The precision of the assay was also
determined in terms of intra- and inter-day variation in the peak
areas of a set of drug solutions on three different days. The intra-
and inter-day variation in the peak area of the drug solution was
calculated in terms of relative standard deviation (RSD).on of a stability-indicating RP–HPLC method for estimation of
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Robustness of the proposed method for atazanavir sulfate was
carried out by the slight variation in ﬂow rate, pH and mobile
phase ratio. The percentage recovery and RSD were noted for
atazanavir sulfate.
2.5.5. Ruggedness
The test solutions were prepared as per test method and in-
jected under variable conditions. Ruggedness of the method was
studied by different analysts.
2.5.6. Detection limit and quantiﬁcation limit
The limit of detection (LOD) and limit of quantiﬁcation (LOQ)
were established based on the calibration curve parameters, ac-
cording to the following formulas:
LOD¼3.3SD/slope
LOQ¼10SD/slope
or detection limit¼3.3s/s, quantiﬁcation limit¼10s/s, where s
is the standard deviation of y-intercept of regression line, and s is
the slope of the calibration curve.
2.6. Forced degradation studies
The speciﬁcity of the method can be demonstrated through
forced degradation studies conducted on the sample using acid,
alkaline, oxidative, thermal, photolytic, and ultra violet (UV) de-
gradations. The sample was exposed to these conditions, and the
main peak was studied for the peak purity, thus indicating that the
method effectively separated the degradation products from the
pure active ingredient [16].
2.6.1. Hydrolytic degradation
Hydrolytic stress testing was performed to force the degrada-
tion of the drug substance to its primary degradation products by
exposure to neutral, acidic and basic conditions over time. Func-
tional groups likely to undergo hydrolysis are amides (lactams),
esters (lactones), carbamates imides, imines, alcohols (epimeriza-
tion for chiral center) and aryl amines.
To initiate hydrolytic studies, a preliminary solubility screen of
the drug substance was performed. Solubility of at least 1 mg/mL
in neutral, acidic and basic conditions was recommended for the
neutral/acid/base stress testing. However, concentration less than
1 mg/mL can be used, if solubility is an issue. In some cases, a co-
solvent may be necessary to achieve the target concentration.
Special attention should be given to the drug substance structure
when an appropriate co-solvent was chosen.
2.6.2. Oxidative degradation
Oxidative degradation of drug substances in pharmaceutical
formulation is well documented. Although exact mechanistic de-
tails about what promotes reaction between drug substance and
molecular oxygen in pharmaceutical formulations are not fully
understood, such reactions are generally thought to be in the ca-
tegory of auto-oxidation process.
There are three major pathways: (i) autoxidation or radical-
mediated oxidation, (ii) peroxide-mediated oxidation and (iii)
photo chemically induced oxidation. Traditionally, dilute aqueous
peroxide solutions have been used for oxidative stress testing of
pharmaceuticals. In addition to the auto-oxidation processes,
peroxide-mediated oxidative degradation can occur, which may
not be observed using radical indicator.
The process of oxidation depends on the amount of oxygen in
the air and the nature of the material it touches. True oxidationPlease cite this article as: S. Dey, et al., Development and validati
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effects as the oxygen causes free radicals on the surface to break
away.
2.6.3. Photolytic degradation
For photolytic degradation, the drug was exposed to the direct
sunlight. Sufﬁcient amount of the drug was taken in a closed petri-
dish and exposed to sunlight. At different time intervals, the drug
was taken out, diluted appropriately and injected into HPLC to
determine the amount of degradation of the drug.
2.6.4. UV-degradation
The goal of UV-degradation studies is to force the degradation
of drug substance via UV and ﬂuorescent condition over time to
determine the primary degradation products. A molecule absorbs
light when an absorption band overlaps to some extent with the
incident light energy and a valence electron in the relevant at-
mosphere rose to an excited state.
A near UV ﬂuorescent lamp has a spectral distribution from
320 nm to 400 nm with a maximum energy emission between
350 nm and 370 nm, and the signiﬁcant proportion of UV should
be in both bands of 320–360 nm and 360–400 nm.
2.6.5. Thermal degradation
To evaluate thermolytic pathways, evaluated temperatures (e.g.
50 °C and 80 °C) in the solid state and/or in solution can be used.
Many compounds began to degrade via different mechanisms
above 80 °C, giving rise to degradation products. To solid-state
stressing, the use of high and low humidity atmosphere of the
evaluated temperatures is appropriate.
To evaluate stability under the temperatures above, stress
conditions were selected based on a conservative estimate of the
Arrhenius expression, a quantitative relationship of reaction rate
and temperature using average activation energy.
A
Ea
RT
Kobs exp= −
3. Results
3.1. Method development
3.1.1. Chromatographic separation
A number of HPLC chromatographic systems were investigated
to optimize the separation of atazanavir sulfate. Retention time for
atazanavir sulfate function of stationary phase (Phenomenex C18
reversed-phase column), the mobile phase and the other opti-
mized chromatographic conditions are shown in Table 1.
3.1.2. Calibration curve
The coefﬁcient of determination (R2), slope and intercept for
atazanavir sulfate were 0.999, 23.427 and 37.732, respectively. The
retention time for atazanavir sulfate was 8.323 min. HPLC overlay
chromatogram of atazanavir sulfate at 249 nm and calibration
curve are shown in Fig. 2.
3.2. Method validation
3.2.1. Linearity, accuracy and precision
The coefﬁcient of determination (R2) for atazanavir sulfate was
0.999 as shown in Fig. 2.
The accuracy of the method was determined and indicated by
the recovery. The results are shown in Table 2.
Intra- and inter-day precision data of the RP–HPLC method for
atazanavir sulfate are presented in Supplementary Table 1 and 2.on of a stability-indicating RP–HPLC method for estimation of
.1016/j.jpha.2013.12.002i
Fig. 2. HPLC overlay chromatogram of atazanavir sulfate at 249 nm. Inset: Calibration curve of atazanavir sulfate.
Table 2
Accuracy of atazanavir sulfate.
No. of prepara-
tions (%)
Concentration (mg/lmL) Recovery (%) Statistical results
Formulation Pure drug Mean SD %RSD
S1: 80 10 8 98.12 98.57 0.71 0.71
S2: 80 10 8 98.21
S3: 80 10 8 99.40
S4: 100 10 10 101.40 100.71 0.68 0.68
S5: 100 10 10 100.03
S6: 100 10 10 100.70
S7: 120 10 12 101.60 100.65 0.84 0.84
S8: 120 10 12 100.40
S9: 120 10 12 99.97
Table 3
Robustness data of the RP–HPLC method at different ﬂow rates for atazanavir sulfate.
Conc. (mg/mL) Flow rate (0.4 mL/min) Flow rate (0.6 mL/min)
Peak area Calc. amt. (mg/mL) Statistical analysis Peak area Calc. amt. (mg/mL) Statistical analysis
50 1207.00 49.92 Mean¼50.06, SD¼0.06, %RSD¼0.14 1208.99 50.01 Mean¼50.06, SD¼0.03, %RSD¼0.07
50 1210.39 50.07 1210.37 50.07
50 1211.27 50.10 1211.36 50.11
50 1210.78 50.08 1209.31 50.02
50 1210.38 50.07 1210.44 50.07
50 1211.03 50.09 1210.38 50.07
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Robustness of the method was studied by deliberate variations
of the analytical parameters such as ﬂow rate (0.570.1 mL/min)
and different pH values. The results are given in Table 3 and 4.
Ruggedness of the method was carried out by different ana-
lysts. The results are displayed in Table 5.
3.2.3. LOD and LOQ
The LOD and LOQ of atazanavir sulfate were determined to be
0.09 mg/mL and 0.23 mg/mL, respectively.Please cite this article as: S. Dey, et al., Development and validati
atazanavir sulfate in bulk, J. Pharm. Anal. (2015), http://dx.doi.org/103.3. Forced degradation studies
3.3.1. Degradation in neutral condition
Neutral degradation of atazanavir sulfate was performed using
distilled water. Ten micrograms of the atazanavir sulfate bulk was
weighed accurately and transferred into a 10mL clean volumetric
ﬂask. The content of the volumetric ﬂask was dissolved in 5 mL of
distilled water. Then the volumetric ﬂask was heated on a water
bath at 80 °C. Samples were prepared for different time intervals
such as 0 min, 30 min, 1 h, 2 h, and 4 h. At different time intervals,on of a stability-indicating RP–HPLC method for estimation of
.1016/j.jpha.2013.12.002i
Table 4
Robustness data of the RP–HPLC method at different pH values for atazanavir sulfate.
Conc. (mg/mL) pH 3.3 pH 3.7
Peak area Calc. amt. (mg/mL) Statistical analysis Peak area Calc. amt. (mg/mL) Statistical analysis
50 1210.96 50.09 Mean¼50.08, SD¼0.07, %RSD¼0.14 1205.68 49.87 Mean¼50.01, SD¼0.07, %RSD¼0.15
50 1211.76 50.12 1208.76 50.00
50 1207.36 49.94 1208.69 49.99
50 1211.06 50.10 1210.60 50.08
50 1212.06 50.14 1209.99 50.05
50 1210.62 50.08 1210.03 50.05
Table 5
Ruggedness data of the RP–HPLC method by different analysts for atazanavir sulfate.
Conc. (mg/mL) Analyst-1 Analyst-2
Peak area Calc. amt. (mg/mL) Statistical analysis Peak area Calc. amt. (mg/mL) Statistical analysis
50 1210.85 50.09 Mean¼50.02, SD¼0.21, %RSD¼0.43 1211.06 50.09 Mean¼50.02, SD¼0.21, %RSD¼0.42
50 1211.32 50.11 1210.99 50.09
50 1211.21 50.10 1211.37 50.11
50 1210.91 50.09 1211.00 50.09
50 1212.22 50.14 1211.02 50.09
50 1199.04 49.58 1199.00 49.58
Table 6
Results of neutral hydrolysis of atazanavir sulfate.
Sl. no. Reten. time
(min)
Area (mV s) Height
(mV)
Area (%) Height (%) W0.5
(min)
1 8.32 1205.24 70.51 100 100 0.28
Total 1205.24 70.51 100 100
S. Dey et al. / Journal of Pharmaceutical Analysis ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 5different sample solutions were taken out and 5 mL of HPLC grade
methanol was added. The sample solution was then sonicated for
5 min and diluted to yield a concentration of 50 μg/mL in the
mobile phase. It was then ﬁltered through a 0.22 μm ﬁlter and
20 μL was injected into the HPLC for analysis. The obtained chro-
matogram was observed for any degradation occurred during the
time. The results are given in Table 6 and Supplementary Fig. S1.
3.3.2. Degradation in acidic condition
Acid degradation of atazanavir sulfate was performed using
0.1 M HCl. Ten micrograms of the atazanavir sulfate bulk was
weighed accurately and transferred into a 10 mL clean volumetric
ﬂask. The content of the volumetric ﬂask was dissolved in 5 mL of
0.1 M HCl and then was subjected to heat on a water bath at 80 °C.
Samples were prepared for different time intervals such as
0 min, 30 min, 1 h, 2 h, and 4 h.
At different time intervals, different sample solutions were ta-
ken out and 5 mL of HPLC grade methanol was added. The sample
solution was then sonicated for 5 min and diluted to obtain a
concentration of 50 μg/mL in the mobile phase. It was then ﬁltered
through a 0.22 μm ﬁlter and injected into the HPLC. The obtained
chromatogramwas analyzed for any degradation happened during
the time. The results are given in Table 7 and Supplementary
Fig. S2.
3.3.3. Degradation in basic condition
Alkaline degradation of atazanavir sulfate was performed using
0.01 M NaOH. Ten micrograms of the atazanavir sulfate bulk was
weighed accurately and transferred into a 10 mL clean volumetric
ﬂask. The content of the volumetric ﬂask was dissolved in 5 mL of
0.01 M NaOH, and then was heated on a water bath at 80 °C.
Samples were prepared for different time intervals such as
0 min, 30 min, 1 h, 2 h, and 4 h.
At different time intervals, different sample solutions were ta-
ken out and 5 mL of HPLC grade methanol was added. The sample
solution was then sonicated for 5 min and diluted to obtain a
concentration of 50 μg/mL in the mobile phase. It was then
ﬁltered through a 0.22 μm ﬁlter and injected into the HPLC. The
obtained chromatogram was studied for any degradationPlease cite this article as: S. Dey, et al., Development and validati
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Supplementary Fig. S3.
3.3.4. Oxidative degradation
For oxidation, the reagent chosen was hydrogen peroxide (3%).
Ten micrograms of the atazanavir sulfate bulk was weighed ac-
curately and transferred into a 10 mL clean volumetric ﬂask.
The content of the volumetric ﬂask was dissolved in 5 mL of
H2O2. Then it was placed at room temperature for degradation.
Samples were prepared for different time intervals such as 0 min,
30 min, 1 h, 2 h, and 4 h. At different time intervals, different
sample solutions were taken out and 5 mL of HPLC grade metha-
nol was added. The sample solution was then sonicated for 5 min
and diluted to yield a concentration of 50 μg/mL in the mobile
phase. It was then ﬁltered through a 0.22 μm ﬁlter and injected
into the HPLC. The obtained chromatogram was studied for any
degradation underwent during the time given. The results are
shown in Table 9 and Supplementary Fig. S4.
3.3.5. Photolytic degradation
For photolysis, 100 mg of the atazanavir sulfate bulk was
weighed accurately and transferred into a clean petridish. Then the
closed petridish was placed under direct sunlight for degradation.
At different time intervals, 10 mg of sample was taken out. From it,
a stock solution of 1000 μg/mL was prepared. Then it was soni-
cated for 5 min and diluted to obtain a working solution of
50 μg/mL in the mobile phase. It was then ﬁltered through a
0.22 μm ﬁlter and injected into the HPLC. The obtained chroma-
togram was observed for any degradation occurred during the
time. The results are given in Table 10 and Supplementary Fig. S5.on of a stability-indicating RP–HPLC method for estimation of
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Table 7
Results showing acidic hydrolysis of atazanavir sulfate.
Sl. no. Reten. time (min) Area (mV s) Height (mV) Area (%) Height (%) W0.5 (min) Results
1 4.77 196.32 11.46 16.59 18.69 0.26 Conc. Rem.¼24.19, %deg¼51.62
2 5.31 382.86 20.57 32.35 33.54 0.27
3 8.39 604.36 29.30 51.06 47.77 0.30
Total 1183.55 61.34 100 100
Table 8
Results showing alkali degradation of atazanavir sulfate.
Sl. no. Reten. time (min) Area (mV s) Height (mV) Area (%) Height (%) W0.5 (min) Results
1 5.18 191.54 12.51 18.39 28.42 0.18 Conc. Rem.¼34.68, %deg¼30.64
2 8.29 849.85 31.52 81.61 71.58 0.37
Total 1041.39 44.04 100 100
Table 10
Results of photolytic degradation of atazanavir sulfate.
Sl. no. Reten. time
(min)
Area (mV s) Height
(mV)
Area (%) Height (%) W0.5
(min)
1 8.34 1211.24 68.51 100 100 0.28
Total 1211.24 68.51 100 100
Table 11
Results of UV degradation of atazanavir sulfate.
Sl. no. Reten. time
(min)
Area (mV s) Height
(mV)
Area (%) Height (%) W0.5
(min)
1 8.30 1209.43 69.26 100 100 0.28
Total 1209.43 69.26 100 100
Table 9
Results of oxidative degradation of atazanavir sulfate.
Sl. no. Reten. time
(min)
Area (mV s) Height
(mV)
Area (%) Height (%) W0.5
(min)
1 5.55 819.38 61.51 40.36 48.16 0.21
2 8.30 1210.56 66.22 59.64 51.84 0.27
Total 2029.94 127.73 100 100
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For UV degradation, 100 mg of the atazanavir sulfate bulk was
weighed accurately and transferred into a clean petridish. Then the
petridish was placed under a UV chamber 30 cm at distance from
the UV lamp. The cover of the petridish was removed for de-
gradation. After 3 h, the UV lamp was switched off and 10 mg of
sample was taken out. From it, a stock solution of 1000 μg/mL was
prepared with the mobile phase, from which 50 μg/mL of working
solution was prepared. It was sonicated and ﬁltered through a
0.22 μm ﬁlter. Twenty microlitres of the sample was injected into
the HPLC.
The degradation of atazanavir sulfate under UV light is given in
Table 11 and Supplementary Fig. S6.
3.3.7. Thermal degradation
Thermal degradation was performed by placing the atazanavir
sulfate bulk in the incubator at 40 °C. Samples were drawn at
deﬁnite time intervals. The weighed amount of sample was added
to 5 mL of HPLC grade methanol and sonicated for 5 min. Volume
was made up to mark with methanol, which is the bulk standard
stock solution of 1000 μg/mL. From the stock, a working standard
solution of 50 μg/mL was prepared with the mobile phase. It was
sonicated and ﬁltered through a 0.22 μm ﬁlter, and 20 μL of the
sample was injected into the HPLC. The obtained chromatogram
was analyzed for any degradation underwent during the time, and
the results are given in Table 12 and Supplementary Fig. S7.4. Discussion
In this RP–HPLC method, the linearity was within the range of
10–90 mg/mL, the method was successfully validated in the opti-
mized conditions, and the validation parameters were within the
limits. In this chromatographic method, the LOD and LOQ of ata-
zanavir sulfate were found to be 0.09 mg/mL and 0.23 mg/mL, re-
spectively. In the present investigation, atazanavir sulfate was
subjected to its stability studies under different conditions as per
the ICH guidelines.Please cite this article as: S. Dey, et al., Development and validati
atazanavir sulfate in bulk, J. Pharm. Anal. (2015), http://dx.doi.org/10From the neutral hydrolytic degradation study of atazanavir
sulfate, it was found that no degradation took place over 4 h in
neutral condition.
The results of acidic hydrolysis showed degradation peaks at
4.77 min and 5.31 min along with the drug peak. The peak area
showed that 51.62% of degradation of the drug occurred when the
drug was kept in 0.1 M HCl at 80 °C up to 4 h.
Atazanavir sulfate upon alkaline degradation in 0.01 M NaOH at
80 °C up to 4 h underwent degradation showing degradation peak
at 5.18 min in the chromatogram. The peak area of the drug
showed that the percentage degradation is 30.64% in the above
condition.
Atazanavir sulfate did not degrade after it was kept under di-
rect sunlight for 21 days. No peak other than the drug peak was
found in the chromatogram of that sample.
Atazanavir sulfate was not degraded after it was kept in the UV
chamber for 48 h.
In the oxidative degradation study atazanavir sulfate showed
no degradation after 4 h of exposure.
The thermal degradation study showed that atazanavir sulfate
was degraded when kept at 40 °C for 15 days. The degradant was
retained at 7.29 min in the chromatogram along with the drug
peak. The drug peak area showed that the degradation of the drug
was 18.97%.
5. Conclusion
The developed RP–HPLC method was found to be suitable for
the analysis of atazanavir sulfate in bulk form, and was found to be
simple, reliable, sensitive, economical and precise.on of a stability-indicating RP–HPLC method for estimation of
.1016/j.jpha.2013.12.002i
Table 12
Results showing thermal degradation of atazanavir sulfate.
Sl. no. Reten. time (min) Area (mV s) Height (mV) Area (%) Height (%) W0.5 (min) Results
1 7.29 236.92 29.62 19.37 38.95 0.21 Conc. Rem.¼40.51, %deg¼18.97
2 8.30 986.53 46.43 80.63 61.05 0.27
Total 1223.46 76.06 100 100
S. Dey et al. / Journal of Pharmaceutical Analysis ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 7The drug atazanavir sulfate was found to be more degraded
when exposed to acidic hydrolysis as it degraded by 51.62% and
least degraded when exposed to neutral hydrolysis, UV-degrada-
tion and oxidative degradation.
Therefore, this RP–HPLC method for estimation of atazanavir
sulfate can be used in various laboratories for its quantitative de-
termination in bulk and pharmaceutical dosage forms.Acknowledgments
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